May 30, 2002

National Advisory Council for Environmental Policy and Technology (NACEPT)
Endocrine Disruptor Methods Validation Subcommittee (EDMVS)

Meeting by Conference Call
June 11, 2002
10:00 AM – 12:00 noon EDT
DRAFT Agenda

Members of the public may join this conference call in person at the conference room in the RESOLVE offices at 1255 23rd St. NW, Suite 275, Washington, DC. To register to participate by phone, please contact Jane Smith, designated federal official for the EDMVS, at smith.jane-scott@epa.gov or 202/564-8476.

Meeting Objective:

- Provide comments and advice on the Steroidogenesis DRP (Tier I).

10:00 – 10:05 Phoning in

10:05 - 10:10 Roll Call

10:10 – 10:40 Steroidogenesis DRP (Tier I)
Jerry Goldman, NHEERL, ORD, EPA

10:40 – 11:40 Discussion on Steroidogenesis DRP

Discussion questions:

1. Does the EDMVS agree with the recommendation of the DRP that EPA should commence prevalidation studies on the sectioned testis assay for steroidogenesis?
2. If yes to #1: Approximately 250 mg or 1/4 of an adult SD rat testis is the sample size generally described by investigators. Should the EPA conduct a study to investigate the sensitivity of the preparations of testicular tissue less the 250 mg to determine an optimal and/or threshold amount to use?
3. The DRP recommends that the test substances listed below be evaluated during prevalidation. Does the EDMVS agree with the choice of test substances?
    - bisphenol A (inhibits steroidogenic signal transduction)
    - lindane (inhibits signal transduction and the StAR protein)
    - ketoconazole (a weak imidazole anti-fungal; inhibits $P450_{scc}$ and aromatase)
    - genistein (a weak phytoestrogen/flavanoid; inhibits 3β-HSD)
    - flutamide (inhibits P450c17)
    - econazole (a potent imidazole; inhibits aromatase)
    - aminoglutethimide (positive control; inhibits $P450_{scc}$)
    - finasteride (negative control; inhibits 5α-hydroxylase)
4. Should EPA investigate the use of MA-10, R2C and H295R cell lines as alternatives to the sectioned testis assay in the EDSP? If so, which cell line?

11:40 – 11:55 Public Comment

Members of the public will be given an opportunity to comment and are requested to focus their comments on issues related to the Steroidogenesis DRP to the extent possible. The amount of time given to each individual will depend on the number of people wishing to provide comment.

11:55 – 12:00 Next Steps and Agenda for July 23-24, 2002 Meeting

12:00 Adjourn